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Diabetic retinopathy (DR) is themost severe of the several ocular complications of diabetes, and in the United States it is the leading
cause of blindness among adults 20 to 74 years of age. Despite recent advances in our understanding of the pathogenesis of DR,
there is a pressing need to develop novel therapeutic treatments that are both safe and eﬃcacious. In the present paper, we identify
a key mechanism involved in the development of the disease, namely, the interaction between neuronal and vascular activities.
Numerous pathological conditions in the CNS have been linked to abnormalities in the relationship between these systems. We
suggest that a similar situation arises in the diabetic retina, and we propose a logical strategy aimed at therapeutic intervention.
1. Introduction
Early Events in the Development of DR the ocular man-
ifestations of diabetes can often strike with little warning,
and despite eﬀorts to prevent its occurrence, approximately
20,000 Americans go blind from diabetic retinopathy every
year [1]. As with many diabetes-related conditions, high
blood glucose levels (hyperglycemia) present as the main
cause of diabetic retinopathy [2]. At an early stage, classified
clinically as nonproliferative DR, there is a thickening of
the capillary basement membranes and a loss of pericytes
in the ocular vasculature [3]. Changes in the mechanical
properties and permeability of the retinal blood vessels
lead to the formation of microaneurysms (i.e., small out-
pouchings from the vessel wall) in capillaries within the
inner nuclear layer [4]. Further vascular deterioration results
in retinal hemorrhages, microretinal infarcts in the nerve
fiber layer of the retina, deposits of cotton-wool spots,
and abnormalities in the electrical activity of the retina
[3, 5–7]. The progressive closure of retinal vessels produces
localized areas of tissue ischemia, venous beading, and other
intraretinal microvascular abnormalities that increase retinal
hemorrhage and exudation. The advancement to prolifera-
tive diabetic retinopathy is viewed to be a consequence of
tissue ischemia and subsequent upregulation of angiogenic
growth factors, for example, vascular endothelial growth
factor (VEGF), and vascular invasion of the inner retina.
Clearly, the challenge is to find a therapeutic approach that
can limit or perhaps prevent the onset of these serious
complications. Here we present a rationale for a novel
therapeutic approach based on the interaction between the
retinal nerve cells and their blood supply. We suggest that
the link between the blood supply of the inner retina
and the concomitant changes in neural activity provides
a mechanism that could be modified pharmacologically to
prevent the onset of diabetes-induced retinopathy.
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Figure 1: Schematic diagram illustrating (i) the normal balance between neuronal activity and vascular function and (ii) the action of 5-
methyl-I4AA in preventing the development of diabetic retinopathy. Arrows at the right and left of the figure represent the opposing forces
that upset (red arrow) or restore (blue arrow) the normal balance between vascular and neuronal function in diabetes. Diabetes disrupts
the functional integrity of the vascular system of the inner retina (red arrow) and tilts the balance indicator toward the production of tissue
hypoxia/ischemia that induces DR. The resultant imbalance in neurovascular coupling (pathway (1)) increases the energy demands of retinal
neurons and glial cells to further exacerbate the condition (dashed red line). 5-methyl-I4AA, by activating the GABAC receptors, suppresses
the activity of inner retinal neurons (blue arrow) and reduces their metabolic demand (dashed blue line). This process reestablishes the
normal balance of the neuron-vascular relationship. See text for additional details.
2. Factors Considered to Be Involved in
the Development of DR
A number of interrelated hyperglycemia-aﬀected pathways
have been identified in the pathobiology of diabetic com-
plications, and a number of agents have been developed to
interrupt pathways implicated in the pathogenesis of DR;
(see [8] for review). Among the most actively studied are
(1) oxidative stress [9–11], (2) polyol pathway activity [12,
13], (3) advanced glycation end-product (AGE) formation
[14, 15], (4) activation of protein kinase C (PKC) isoforms
[16, 17], and (5) increased hexosamine pathway flux [18].
However, the linkage between any particular pathway and
the development of DR is still largely speculative. Although
several promising drugs have been tested extensively, few
have proven beneficial owing perhaps to the fact that
treatment is typically implemented when there is already
evidence of severe retinopathy.
A new approach that could provide intervention earlier
in the disease to delay or prevent the onset of retinopathy
would clearly be of great benefit in the management of
DR. We suggest that reestablishing the balance between
neuronal activity and vascular function will suppress hypoxia
in diabetic retinas and provide therapeutically beneficial
eﬀects in cases of DR. In this connection, it is important to
recognize the link between the neural and vascular systems
and their functional interdependence. This is clearly evident
in the inner layers of the retina where the nerve cells are
susceptible to the metabolic or hypoxic/ischemic vascular
insult resulting from diabetes. In the sections that follow,
we will present evidence of neurovascular coupling in the
nervous system, describe the ways in which the regulation of
neuronal activity could serve as a means of reducing hypoxic
stress in the diabetic retina, and develop a rationale for a
novel therapeutic approach based on the interaction between
the retinal nerve cells and their blood supply. Specifically,
we propose the use of a GABAC receptor agonist, 5-methyl-
I4AA, to suppress the neural activity of the inner retina,
thereby establishing a normal neurovascular relationship to
relieve diabetes-induced ischemia.
The essential features of this mechanism are illustrated
schematically in Figure 1. A majority of the energy con-
sumption in the nervous system is associated with neu-
ronal activity and the cycling of neurotransmitters. Cell-
cell and cell-matrix signals between neurons and glial cells
trigger the regulatory mechanisms of the vascular system.
Conversely, the vasculature supports neuronal activity and
its metabolic demands. In normal circumstances, hemody-
namic neurovascular coupling ensures the balance between
neuronal activity and vascular function. Under diabetic
conditions, however, the capacity of the vascular system
is upset, thereby compromising the blood supply to the
retina, causing tissue hypoxia, and creating an imbalance
in neurovascular coupling. Prolonged tissue hypoxia leads
eventually to the development of diabetic retinopathy. We
propose that activating the GABAC receptors on retinal
neurons with 5-methyl-I4AA will suppress the activity of
inner retinal neurons and reestablish a normal neurovascular
relationship to relieve tissue hypoxia. Thus, treating the eye
with 5-methyl-I4AA may be able to prevent or delay the
development of retinopathy under diabetic condition.
3. NeuroVascular Interactions in the CNS
Inmost tissues, requirements for nutrients fluctuate in accor-
dance with variations in activity. In the CNS, for example,
there is extensive experimental evidence that cerebral blood
flow is modulated by a variety of sensory stimuli. These
findings, which have profoundly impacted our understand-
ing of the relationship between increased neuronal activity
and increased cerebral blood flow, have led to the mapping
of brain activation now widely used in the diagnosis of
brain pathologies [19]. Neurovascular coupling plays an
important role in the maintenance of normal function in
the nervous system, and defects in this relationship often
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lead to various forms of disease [20–22]. For example,
stroke is now recognized as involving multiple cell types that
disrupt the “neurovascular unit” [23, 24]. Ischemic damage
results from the excessive activation of glutamate receptors,
the recruitment of inflammatory cells, the overproduction
of free radicals, and the initiation of apoptosis. It is now
widely accepted that brain function involves the complex
interactions between multiple cells types, including neurons,
glial cells, and the microvascular endothelial cells comprising
the cerebral vasculature [25, 26]. Thus, in addition to stroke,
disruption of this neurovascular coupling has been impli-
cated in Alzheimer’s disease [27], epilepsy [28], Parkinson’s
disease, migraine, and other disorders of the CNS [20, 29].
Although a number of studies have focused on cellular and
molecular mechanism of neurovascular coupling in the CNS,
there are few that examine the relationship between neural
activity and vascular function in the eyes of living animals
(cf. [21, 30]).
4. Neurovascular Relationships in
Mammalian Retina
The retina is arguably the most metabolically active tissue
in the body, demanding the highest rate of blood supply
per unit tissue weight [31]. However, the metabolism
of its cellular components undergoes significant changes
depending on both internal (e.g., blood pressure variations)
and external (e.g., levels of photic exposure) factors. To meet
these varying conditions, the retinal vasculature responds
with regulatory mechanisms to control the blood supply to
the tissue. Oxygen and nutrients are delivered to the retinal
tissue by two separate pathways: the choroidal circulation
supports cells of the outer retina (primarily photoreceptors
and RPE), whereas the retinal circulation, subserved by the
central retinal artery and vein, provides nourishment to
inner retinal neurons (bipolar, amacrine, and ganglion cells)
where the vascular abnormalities associated with diabetic
retinopathy appear to be most pronounced.
A number of studies have demonstrated that retinal
blood circulation can be regulated in accordance with the
activity of inner retinal neurons as well as in response to
activation of glial cells [21]. In addition, using deoxyglucose
as a tracer for metabolic activity, it has been shown that
a flickering light stimulus selectively elevates the metabolic
demand of cells in the inner retinal layers of rabbit [32]
and monkey retinas [33]. Similarly, light-induced changes
in retinal vascular oxygen tension have been recorded in
rat eyes [34]. In addition, the increase in optic nerve head
PO2 resulting from flickering light has been detected with
phosphorescence imaging [35], and changes in intravascu-
lar PO2 have been reported based on the blood oxygen
level-dependent signals obtained from magnetic resonance
imaging [36]. These metabolic changes are associated with
enhanced blood circulation in the retinal vasculature, which
has been termed the visually-evoked hemodynamic response
[37]. Thus, the activity of retinal neurons produces a
metabolic demand that can lead to free-radical production
in blood vessels compromised by DR.
5. Diabetic Effects on the Function of Retinal
Neurons and Vasculature
Diabetes has a significant impact on the functional status of
the retinal vasculature; alterations in retinal blood flow have
been observed in both animal models and human patients;
(see [38] for review). Retinal oxygenation measured with
fMRI techniques showed a reduction of retinal PO2 after the
onset of hyperglycemia in rats made diabetic by ingestion
of a high-galactose diet [39], and increased oxidative stress
has been postulated as one of the major contributors in
the development of diabetic retinopathy [40–42]. Diabetes
and hyperglycemia increase the formation of reactive oxygen
species (ROS), including nitric oxide (NO), superoxide
(O.−2 ), and their product peroxynitrite (ONOO−) [43–46].
Increased formation of ROS is one of the early cell signals
in diabetic retinopathy [46–48], and elevated nitrotyrosine
levels in association with diabetes have been reported in
a number of studies [46, 49, 50]. Diabetes impairs both
neuronal activity and vascular function in the retina [51–54]
such that vascular abnormalities cause an imbalance between
the inner retinal blood supply and the metabolic demand of
retinal neurons; these changes result in hypoxia. Conversely,
a reduction in neural activity diminishes the stimulation
of vascular responses. To what extent these functions are
causally related is still an unanswered question [51], since the
mechanisms that link neural impairment to the development
of vascular abnormalities and retinal hypoxia in diabetes
have not been adequately investigated.
In human diabetic patients, there is a reduction in the
hemodynamic response of retinal vessels to flicker light
stimulation [39], which reflects most likely the underlying
hyperglycemia-induced compromise of the microvascula-
ture. In these circumstances, the endothelial cells of the
retinal vasculature probably have an impaired ability to
liberate endothelial nitric oxide synthase, which is important
for their autoregulation [55]. Blood flow is also impaired
by enhanced plasma viscosity, increased platelet aggregation,
and decreased red blood cell deformability [56, 57]. These
changes lead, in turn, to perfusion problems and local areas
of retinal ischemia [58, 59], which have long been associated
with the development of DR [60–62]. Changes in the blood
supply to the inner retina exert a profound influence on
the metabolism and activity of the retinal neurons, and
consequently both the neuronal and vascular systems are
compromised. However, whereas diabetic retinopathy is
typically diagnosed clinically by abnormalities in the retinal
microvasculature after prolonged hyperglycemia, there is
well-documented evidence to indicate that neural deficits
occur early in the course of the disease; (for reviews see;
[52, 63]). For example, psychophysical tests have shown color
vision defects and a reduction in contrast sensitivity [64],
and neurosensory changes have been detected before the
onset of observable retinopathy by means of the flash ERG
[65] and multifocal ERG [66, 67]. In addition, degeneration
of retinal ganglion cells has been reported in patients at
early stages of diabetes [53], and our studies demonstrated
diabetes-induced neural defects in 12-week old STZ-treated
rats when measured by the ERG and with patch-clamp
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recordings from individual retinal neurons [68, 69]. Clearly,
it is uncertain whether neural or vascular defects represent
the earliest manifestations of the disease process.
6. The GABA Receptor and
Oscillatory Potentials
The results of the studies cited above have led us to hypoth-
esize that inhibiting the activity of inner retinal neurons will
reduce the metabolic demands of the retinal cells and thereby
diminish the diabetes-induced tissue hypoxia. Since hypoxic
stress induces retinal cells to release a series of angiogenic
factors that promote the clinical manifestations of DR, we
sought an agent that would reduce neuronal activity in the
inner retina, that is, slow their metabolic rate. Thus, it was
necessary to identify an inhibitory neurotransmitter that
suppressed the activity of inner retinal neurons, as well as
an electrical response that originated from these neurons.
Earlier studies have provided extensive information on these
issues.
It is generally recognized that GABA (γ-aminobutyric
acid) is the most prominent inhibitory neurotransmitter in
the retina and CNS, whereas oscillatory potentials (OPs), a
series of high-frequency wavelets superimposed on the ERG
b-wave, are light-evoked electrical responses derived from
inner retinal neurons. Numerous studies have shown that
activation of GABA receptors diminishes the amplitude of
OPs [70–72] and that OPs are very sensitive to disruption
of GABAergic inhibitory neuronal pathways [70]. If, as we
suggest, activation of GABA receptors will suppress neuronal
activity, alleviate retinal hypoxia, and eﬀectively reestablish
the balance between the inner retinal blood supply and the
metabolic demand of retinal neurons in DR, it then becomes
essential that we identify the subtype of GABA receptor to be
activated and the most eﬀective agent to mediate the desired
eﬀect.
7. GABA and the Family of GABA Receptors
GABA is the main inhibitory neurotransmitter in both
the CNS and retina [73–75]. Indeed, about 30–40% of all
neuronal synapses within the mammalian brain are thought
to be GABAergic [76–78]. In adult mammalian retina,
where GABA mediates the majority of inhibitory synap-
tic transmission, amacrine cells are the main GABAergic
inhibitory interneurons. These cells extend processes laterally
to synapse with neighboring neurons in the inner plexiform
layer, where they make inhibitory connections with bipolar
cell terminals, ganglion cells, and other amacrine cells in the
inner retina. In addition to other functional roles, GABAergic
transmission is involved in the formation of complex
receptive fields and directional sensitivity of ganglion cells
[79–82].
The inhibitory eﬀects of GABA are mediated by three
major classes of GABA receptor present on postsynaptic
neuronal membranes, termed GABAA, GABAB, and GABAC
receptors. Each has a distinct molecular structure and unique
functional and pharmacological properties [83–87]. GABAA
receptors are a family of ligand-gated chloride channels that
mediate rapid inhibitory reactions and have a diverse molec-
ular composition consisting of mixtures of six subunits.
However, they are not highly expressed on retinal bipolar
cells, and, most importantly, they inactivate quickly. In
contrast, GABAB receptors belong to the G-protein-coupled
receptor superfamily, whose inhibitory actions are mediated
indirectly by second messengers that gate potassium and
calcium channels. Although present on bipolar cells of
lower vertebrates [88], GABAB receptors are not seen in
mammalian bipolar cells [89, 90].
Because of its localization and response properties, the
GABAC receptor is of special interest in the context of our
hypothesis. It is composed for the most part of GABA ρ
subunits, three of which (ρ 1–3) have been cloned from
mammalian retinal cDNA libraries [91–93]. The GABA ρ
subunits are distributed predominantly on retinal neurons,
although their expression is also detected in other parts of
the brain [85, 86, 94–96]. The unique physiological and
pharmacological properties of the GABAC receptors have
been summarized in a series of reviews [75, 85–87, 97].
Particularly noteworthy is the fact that GABAC receptors
are located predominantly on the axon terminals of retinal
bipolar cells where they contact inner retinal neurons [98,
99]. Equally significant is their slow kinetics of activation and
deactivation in response to GABA, that is, the response is
sustained with little sign of desensitization [90, 100, 101].
From a therapeutic standpoint, the restricted distribution
reduces potential side eﬀects, whereas its nondesensitizing
properties allow for sustained inhibition of neuronal activity.
Thus, the prolonged inhibitory eﬀect on bipolar cell activity
by externally applied agonists can be expected to significantly
reduce the excitability of inner retinal neurons. Moreover,
the GABAC receptor is highly sensitive to agonists [100,
101], and, consequently, relatively low drug doses will be
required to achieve the desired inhibition of inner retinal
neurons.
8. Some Experimental Studies
Our proposal to use a GABAC receptor agonist to activate this
receptor subtype is not entirely conjectural. Several studies
have shown that activation of GABA receptor-mediated
inhibition can reduce hypoxia-induced glutamatergic
activity to prevent cytotoxic eﬀects on neurons in the CNS
[102–104]. During the past decade, we have carried out an
extensive series of studies on the localization, functional
properties, and molecular composition of the GABAC
receptor [85, 101, 105–110] and we have examined the
pharmacological properties of the GABAC receptors on
neurons in the retinas of normal and streptozotocin-induced
diabetic rodents [68, 69]. As a first step in analyzing the
eﬀects of neuronal inhibition on retinal vasculature, we
conducted a study to determine the eﬃcacy of the GABA
receptor agonist 5-methyl-I4AA on the response properties
of retinal neurons and its eﬀects both on visual performance
and the retinal vasculature. It had been shown that methyl
substitution at the 5 positions of the imidazole-4-acetic acid
(I4AA) molecule acts as a specific, highly potent GABAC
receptor agonist [111]. A gift of 5-methyl-I4AA from
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Figure 2: Membrane current response elicited from an isolated
rat retinal bipolar cell by 5-methyl-I4AA (100μM) in normal
saline (control), when coapplied with 100 μM bicuculline, a GABAA
receptor antagonist (Bic.), or coapplied with 250 μM TPMPA, a
GABAC receptor antagonist (TPMPA). Note that bicuculline has
a negligible eﬀect on the 5-methyl-I4AA-induced current, whereas
TPMPA suppresses the response almost completely. Both actions
confirm that there are few or no GABAA receptors involved in 5-
methyl-I4AA response elicited from rat bipolar cells.
Dr. Bente Frolund at University of Copenhagen, Denmark,
allowed us to test its eﬀects on rat retinal bipolar cells.
Figure 2 shows an example of current recordings
obtained from isolated rat bipolar cells. With the mem-
brane potential held at −60mV, application of 100 μM 5-
methyl-I4AA induced a sustained inward current (Figure 2,
Control). Although rat bipolar cells are said to contain
both GABAA and GABAC receptors [68, 99, 112], the
5-methyl-I4AA-induced response was insensitive to the
GABAA receptor antagonist bicuculline, that is, the response
to the coapplication of 100 μM bicuculline with 5-methyl-
I4AAwas virtually the same as that elicited by 5-methyl-I4AA
alone (Figure 2, Bic). In contrast, 5-methyl-I4AA responses
were greatly reduced when coapplied with 250 μM TPMPA,
a GABAC receptor antagonist (Figure 2, TPMPA). These
findings indicate that the eﬀect of 5-methyl-I4AA on rat
bipolar cells is mediated almost exclusively by the GABAC-
receptor. The dose-response relation for 5-methyl-I4AA
induced current on rat bipolar cells is shown in Figure 3.
The data were fit by a Hill equation with an EC50 of 35 μM,
a value that can serve as a guide for selecting drug dosages
with which to test the eﬀects of 5-methyl-I4AA in inhibiting
neuronal activity.
To determine the eﬀect of diabetes on individual bipolar
cells, we recorded GABA-elicited responses from isolated
bipolar cells of diabetic rat retinas and compared them with
the responses elicited from cells of age-matched normal
retinas [68]. The results revealed that application of GABA
generated a large, sustained inward current that deactivated
slowly. When we coapplied bicuculline, a specific GABAA
receptor blocker, the response was reduced by about 20%,
indicating that the response elicited from the bipolar cell is
generated primarily by activation of GABAC receptors, with
only a small contribution from GABAA receptors. Moreover,
the dose-response relation of the GABAC receptor-mediated
0
0.2
0.4
0.6
0.8
1
1 10 100 1000
5-methyl-I4AA (µM)
N
or
m
al
iz
ed
re
sp
on
se
Figure 3: Dose-response relation of 5-methyl-I4AA-elicited current
on rat retinal bipolar cells. Data were derived from the average of 6
cells and fit with a Hill equation with an EC50 of 35 μM.
response showed that the maximum current response was
greater in cells derived from diabetic animals than those from
age-matched controls and that the diabetic cells exhibited
a higher GABA sensitivity than those from the normal
control group. The enhanced GABAC receptor activity in
diabetic retinas indicates that activation of this receptor will
maintain their inhibitory action in the retina even under
hyperglycemic conditions.
We also examined the distribution and expression of
the GABAC receptor subunits in diabetic retinas using
immunohistochemical techniques [68]. We found, in agree-
ment with earlier studies [98], that the majority of GABAC
receptors are expressed in the inner plexiform layer (IPL),
most prominently on the bipolar cell terminals. The levels
of GABAC receptor expression in the diabetic retina were
slightly higher than in control animals [69]. The fact that a
similar GABAC receptor expression pattern was observed in
the diabetic retina indicated that long-term hyperglycemia
does not alter the pattern of GABAC receptor expression in
the retina. Clearly, the GABAC receptor could serve as a target
for modulating neural activity under diabetic conditions.
In addition to extensive study of the localization, func-
tional properties, and molecular structure of the GABAC
receptor, we examined a number of drug-induced responses
in normal rats and those made diabetic by injection of
streptozotocin. In order to demonstrate the eﬃcacy of 5-
methyl-I4AA on the activity of inner retinal neurons, we
recorded the oscillatory potentials (OPs) of the electroretino-
gram (ERG) in response to a brief light flash (Figure 4).
These components of the ERG, a series of wavelets that
ride on the ascending phase of the ERG b-wave [113, 114],
provide a noninvasive measure of the electrical response of
neurons in the inner retina, where GABAergic mechanisms
play a critical role in their generation [71]. Figure 4 compares
the OPs elicited from a normal rat eye injected with saline
(control) with those from the fellow eye that had received
an intravitreal injection of 5-methyl-I4AA (1mM calculated
vitreous concentration). It is clear that OPs isolated from
the complex ERG waveform using a digital zero-phase band-
pass filter (40–200Hz) were greatly reduced by intravitreal
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Figure 4: The eﬀect of intravitreal injection of 5-methyl-I4AA
(1mM) on oscillatory potentials (OPs) recorded from rat eyes. The
OPs, which arise from the activity of inner retinal neurons, were
elicited after 1-hour dark adaptation; saline-injected eyes served as
control. OPs were derived from digital band-pass filtered recordings
(40–200Hz) of the flash-evoked ERG. Arrows indicate the onset of
a light flash (3 cd.s/m2).
injection of 1mM 5-methyl-I4AA (on average to about 23%
of the response of saline-injected eyes).
Before suggesting the use of any drug, it is of paramount
importance to demonstrate that it does no harm. We
therefore performed an experiment to determine whether
intravitreal injections of 5-methyl-I4AA (12mM) into both
eyes of two normal rats had any deleterious eﬀect on the
animals’ visual performance. Using a virtual optomotor
system (OptoMetry [115]) in Dr. Zhuo-hua Pan’s laboratory
(Wayne State University, Detroit, MI), we measured opto-
motor responses 24 hours after injection and compared the
results with those obtained from two uninjected rats that
served as control. Contrast sensitivity, measured at 6 spatial
frequencies, was similar for the four animals, indicating that
5-methyl-I4AA did not grossly interfere with visual function
(data not shown). It was not possible at this stage to deter-
mine whether more subtle changes in vision had occurred.
We carried out a pilot experiment to examine the
protective eﬀects of intravitreal injection of 5-methyl-I4AA
in 3 diabetic rats. 12 weeks after induction of diabetes with
STZ, one eye of each animal was injected with 5-methyl-
I4AA (vitreous concentration of about 1mM), whereas the
other eye was injected with saline and served as control. After
4weeks of drug administration (one injection per week), rats
were sacrificed and the retinas were isolated. The expression
of diabetes-induced biomarkers was examined by immuno-
histochemistry and real-time RT-PCR techniques. As noted
earlier, tyrosine nitration has been used as a biomarker for
the development of diabetic retinopathy [46, 49, 50, 116],
and thus changes in nitrotyrosine expression can be used
to evaluate the protective role of GABAC receptor agonists
in the diabetic retina. As shown in Figure 5, we observed
an increase in tyrosine nitration in the diabetic retina and
found that application of 5-methyl-I4AA reduced its level of
expression. In the diabetic animal (Figure 5(a)), the highest
expression of nitrotyrosine was observed near retinal blood
vessels (arrows) and in the cell bodies of retinal ganglion
cells (arrowheads). Enhanced nitrotyrosine expression was
also seen in the IPL although the fluorescence was less
intense. After treatment with 5-methyl-I4AA (Figure 5(b)),
an intense nitrotyrosine signal persisted in blood vessel
areas (arrows), whereas the expression in retinal ganglion
cell bodies and in IPL was significantly reduced. We used
a published protocol to quantify the level of nitrotyrosine
expression in the IPL [117], and four retinal sections from
each of 3 diabetic rats were examined. Averaged results
shown in Figure 6 confirmed that 5-methyl-I4AA treatment
produced a significant reduction in nitrotyrosine expression
(P < .05).
Lastly, we examined iNOS expression, another biomarker
of the diabetic retina [116, 118–121]. Using real-time RT-
PCR techniques, we measured iNOS expression in 3 diabetic
rats receiving 5-methyl-I4AA treatment in one eye, whereas
the fellow eye was injected with saline and served as
control [69]. After 4 weeks of drug administration (one
injection per week), the expression level of iNOS in diabetic
retina was significantly reduced after treatment with the
GABAC receptor agonist, that is, application of 5-methyl-
I4AA exhibited a protective eﬀect on the diabetes-induced
signal in rat retina (Figure 7).
The findings obtained in our animal studies provide good
evidence that a GABAC agonist aﬀords a form of pharma-
cological intervention that is capable of reestablishing the
balance between the blood supply and neural activity and
thus relieve hypoxia in the diabetic retina. The feasibility of
this novel therapeutic approach in preventing or delaying
the onset of retinopathy in diabetes should be further tested
in animal models. If successful, the proposed therapy will
have high translational value for the treatment of human
patients. It is also noteworthy that reducing neural activity by
activating GABA receptors in the retina may prove beneficial
for preserving visual function under other pathological
conditions, such as glaucoma. Clinically, glaucoma manifests
as a loss of retinal ganglion cells and is thought to be caused
in large part by glutamate-induced excitotoxicity. Activating
the GABAC receptors on bipolar cell terminals will be an
eﬀective means of reducing the release of glutamate, thus
providing the ganglion cells with a measure of protection
from exposure to cytotoxic levels of glutamate.
9. Some Issues for Consideration with
This Pharmacological Approach
Although no adverse eﬀects were seen with the introduction
of 5-methyl-I4AA, there are reports that activation of GABA
receptors could exacerbate the neuronal injury induced by
excitatory agents or oxygen-glucose deprivation, especially
for neurons at an early embryonic stage [122, 123]. This
is probably related to the high intracellular Cl− concentra-
tion of immature neurons, on which GABA often has an
excitatory action. Indeed, it has been shown that GABA is
protective for mature cortical neurons under hypoxia but
toxic for immature cells [124]. Thus, the unique properties of
the GABAC receptor expressed in retinal neurons could serve
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Figure 5: Nitrotyrosine expression in diabetic rat retina. Eyes were treated with saline (b) or with 5-methyl-I4AA (treatment). Nitrotyrosine
expression was revealed by immunostaining with a polyclonal antibody (Chemicon) on cryosections of the retina. Arrows point to retinal
blood vessels in both retinas. Arrowheads show staining of retinal ganglion cells in the diabetic retina but not in the treated retina. PR:
photoreceptor layer, ONL: outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear layer, IPL: inner plexiform layer, and GCL:
ganglion cell layer. Scale bar: 50 μm.
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Figure 6: Bar graph illustrates nitrotyrosine fluorescence intensity
in diabetic retina and those treated with 5-methyl-I4AA. Measure-
ments from 3 animals show a significant reduction in fluorescence
intensity (asterisk) after 5-methyl-I4AA.
as an ideal target for protecting against hypoxia associated
with diabetes.
GABAC receptor agonists probably have a limited capac-
ity for regulating the metabolic rate of retinal neurons,
since a large component of the energy consumed by the
cells provides for their “housekeeping” needs. However, it
is unlikely that activating the GABA receptor on retinal
neurons will shut down completely the metabolism of the
cell. This could be the reason for a recent report citing the
inability of a GABA receptor agonist in preventing ischemia-
reperfusion injury in the retina [125]. On the other hand,
diabetes is a chronic disease, and the hypoxia induced by
diabetes in the retina is relatively mild. Reducing neuronal
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Figure 7: Real-time RT-PCR measurements of iNOS expression
in the retinas of diabetic and 5-methyl-I4AA-treated rat eyes. The
amount of RNA in each sample was determined by the value of Ct,
the cycle number for the amount of PCR product needed to reach
the fluorescence threshold. When normalized to L7 expression, a
housekeeping gene of 60S ribosomal protein, the expression level of
iNOS in diabetic retina was significantly reduced (i.e., a higher ΔCt
value) after treatment with the GABAC receptor agonist.
activity and metabolic demand in the diabetic retina could
profoundly aﬀect the development of DR.
These considerations aside, 5-methyl-I4AA is clearly a
highly potent agent for activating the GABAC receptor and
should be potentially a useful drug for suppressing or delay-
ing the onset of diabetic retinopathy. The novel approach for
preventing the development of diabetic retinopathy that we
propose, if more extensive studies in animal models confirm
its beneficial eﬀects, will have important and immediate
translational value for treating human diabetic patients.
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